AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02301780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days.
Study NCT02301780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days.
Study NCT03804801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hibiscus Sabdariffa
Description: The extract of the plant Hibiscus Sabdariffa, also known as sour or red tea
Study NCT04541888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA Ophthalmic Gel
Description: The CsA eye gel of 0.3 g: 0.15 mg
Study NCT04541888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04541888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypromellose Eye Drop
Description: Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop
Study NCT04541888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypromellose Eye Drop
Description: Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop
Study NCT03612999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom continuous glucose monitor
Description: Continuous glucose monitors (CGMs) record subjects glucose levels
Study NCT03612999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit activity tracker
Description: Activity trackers will record subjects' physical activity, heart rate, and sleep.
Study NCT03612999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subjects record daily activity
Description: Subjects will record their daily activities, either on paper or on a secure texting app.
Study NCT03612999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subjects record psychological state
Description: Subjects will record their psychological state, either on paper or on a secure texting app.
Study NCT03705884 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 18F-FDG
Description: Hybrid 18F-FDG PET/MR imaging for observational diagnostic purposes.
Study NCT03705884 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Oral course of Prednisolone for treatment of sarcoidosis (patient cohort) or as control (healthy volunteer cohort)
Study NCT04018131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo drug
Study NCT02773901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000
Study NCT02673736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX73086
Study NCT03197480 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept Injection [Eylea]
Description: All subjects will receive 4 monthly intravitreal injections of aflibercept
Study NCT01837264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magellan®
Study NCT01999816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Redesign
Description: Individualized program for lifestyle redesign aimed at decreasing the risk of medically serious pressure ulcers led by licensed occupational therapists trained in the implementation of the lifestyle redesign program
Study NCT03340597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: F901318 tablet
Study NCT00425932 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
Study NCT03014583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spectra™ system
Description: Neurostimulation procedures
Study NCT02513160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone Dipropionate 640
Description: Beclomethasone Dipropionate 640 mcg BAI
Study NCT00999479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate and ethinyl estradiol tablets, USP
Description: Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.~Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc.
Study NCT00999479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ferrous fumarate (placebo) tablets
Description: Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets. Each brown tablet contains ferrous fumarate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
Study NCT04478279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm
Study NCT04478279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide
Study NCT04478279 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation
Study NCT01742767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatinum
Study NCT01742767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatinum
Study NCT01742767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT01742767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Study NCT01060163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery
Study NCT01060163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline served as placebo
Study NCT03263819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test
Description: 75 grams of glucose
Study NCT04130919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilpisertib
Description: Tablets administered orally once daily
Study NCT04130919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally once daily
Study NCT02351973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorthiazide
Description: HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
Study NCT02351973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Description: Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
Study NCT02351973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorthiazide and Amiloride
Description: HCTZ 12.5 to 25mg \& + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
Study NCT01562431 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Feed-back
Description: Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
Study NCT01823315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX 1
Description: MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5
Study NCT01823315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX 1
Description: MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5
Study NCT01823315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX 2
Description: MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, >4h)
Study NCT01823315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Act-d
Description: Act-d 0.6mg/m(2), IV, on day1,2
Study NCT05334602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Addition of dermal fat graft as protection over bone graft
Description: A barrier membrane
Study NCT03553589 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling (10 mL) prior to standard care (e.g. surgery, medical treatment)
Study NCT03165526 — intervention group
Intervention type: DEVICE
Intervention: AMPLATZER™ Post-infarct Muscular VSD Occluder
Description: The AMPLATZER™ PIVSD Occluder is intended for percutaneous transcatheter closure of post-myocardial infarct muscular VSDs in patients who are not satisfactory surgical candidates.
Study NCT01878656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The investigators decrease to 1 minimal alveolar concentration(MAC) of anesthetic combination of sevoflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, sevoflurane and nitrous oxide are discontinued.
Study NCT01878656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: The investigators decrease to 1 MAC of anesthetic combination of desflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, desflurane and nitrous oxide are discontinued.
Study NCT04192617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM03
Description: SM03: 600 mg intravenous (IV)
Study NCT04192617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 600 mg intravenous (IV)
Study NCT04192617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 600 mg intravenous (IV)
Study NCT02507895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MI-BCI
Description: Subjects will be seated comfortably in front of a computer screen. An EEG cap will be comfortably worn over the head of the subject to record EEG traces of any activated cortical areas. If subjects are able to activate the device and are agreeable to participate in the second phase of the study, they will be enrolled in a 4-week BCI-MI training program of 12 sessions. Subjects will be required to perform 160 trials of MI altogether with assigned rest periods (5 mins) every 40 trials. Each session will last approximate 45 minutes excluding set up time.
Study NCT03185975 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: at-home test kit
Description: Transgender youth in the control arm will receive test kits, but will not receive any testing intervention. Once individual results are reported, participants will be contacted via phone or email by study staff with options for referrals to services. Participants will complete follow-up surveys at 3, 6, 9, and 12 months post-testing.
Study NCT03185975 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing and Certified Testing and Referral
Description: Transgender individuals randomized to the experimental group (MI/CTR) will receive HIV counseling and testing via an online, HIPPA-compliant videoconferencing service. The session will last less than one hour and focus on HIV testing, prevention strategies, and/or linkage to HIV care, depending on the individual's test results. Participants will complete follow up surveys at 3, 6, 9 and 12 months.
Study NCT04192617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: methotrexate: 7.5-20 mg/week oral
Study NCT04192617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: methotrexate: 7.5-20 mg/week oral
Study NCT05086081 — intervention group
Intervention type: DRUG
Intervention: Ticagrelor 90mg
Description: Any ticagrelor dispensing claim is used as the exposure group
Study NCT05086081 — intervention group
Intervention type: DRUG
Intervention: Prasugrel 10mg
Description: Any prasugrel dispensing claim is used as the reference group
Study NCT01098734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WBI-1001
Description: A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).
Study NCT01098734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WBI-1001
Description: A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).
Study NCT02175407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707
Description: oral
Study NCT02175407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: oral
Study NCT04261933 — intervention group
Intervention type: DRUG
Intervention: semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study NCT02236754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 18 F-FP-DTBZ
Description: The drug, no carrier added \[18 F\]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce \[18 F\]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 millicuries (mCi) of \[18 F\]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
Study NCT02236754 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: PET Scanning
Description: Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
Study NCT00493363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Artesunate 2 mg/kg/day for 7 days
Study NCT04443881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 149 MG/ML Prefilled Syringe [Kineret]
Description: Anakinra (100 mg/ 6 hours) i.v infusión during 15 days
Study NCT00493363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate + Mefloquine
Description: Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
Study NCT01732393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral quercetin capsules
Description: 10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
Study NCT01732393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00254254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide - Exenatide - Placebo
Description: Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.
Study NCT00254254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide - Placebo - Exenatide
Description: Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
Study NCT00254254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Exenatide - Exenatide
Description: Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
Study NCT02740933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demeclocycline
Study NCT03812146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC-TIME
Description: PC-TIME consists of five, 30-minute sessions delivered over 8 weeks. Intervention will be delivered by a behavioral health provider and will consist of brief Prolonged Exposure for PTSD integrated with aspects of the Motivational Interviewing counseling approach.
Study NCT01511900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 1004
Description: Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004
Study NCT01511900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort
Study NCT01511900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 1004
Description: Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 2 -9 subjects will be treated with CAT-1004
Study NCT01511900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 1004
Description: Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 3-9 subjects will be treated with CAT-1004
Study NCT01511900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 1004
Description: Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 4-9 subjects will be treated with CAT-1004
Study NCT01511900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 1004
Description: Multiple dose oral administration daily for 14 days of CAT 1004 at dose level TBD-9 subjects will be treated with CAT-1004
Study NCT02971345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent and Iodine-125 seed strand implantation
Description: The patent second-order branch of the intrahepatic portal vein was punctured with a 22-gauge Chiba needle under ultrasound guidance.Stent and Iodine-125 seed strand are implanted by two 0.035-inch,150-cm-long wire.
Study NCT02971345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent
Description: Bare stent should be placed through a 7-F, 23-cm-long sheath over the wire.
Study NCT02971345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iodine-125 seed
Description: The number of Iodine-125 seeds planned to be implanted was calculated by the following formula: N = length of obstructed main portal vein (mm)/4.5 + 4. These seeds were arranged linearly and sealed into a 4-F catheter continuously to construct a Iodine-125 seed strand.
Study NCT02971345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: Epirubicin 30-60 mg per patient,depending on the situation of the patient.
Study NCT02971345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: Epirubicin 30-60 mg per patient,depending on the situation of the patient.
Study NCT02971345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultra-fluid lipiodol
Description: Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .